阿托伐他汀对心房颤动患者血浆C-反应蛋白及脑卒中的影响

Effect of Atorvastatin on the Level of C-Reactive Protein and＇on the Incidence of Stroke in Patients with Atrial Fibrillation

目的探讨阿托伐他汀对永久性心房颤动患者血浆CR．P及卒中发生率的影响。方法选择96例永久性心房颤动患者，随机分为对照组（常规治疗组）和观察组（常规治疗基础上加阿托伐他汀20rag／d），随访观察12个月，观察血浆C反应蛋白（CRP）水平及缺血性脑卒中发生的情况。结果治疗后观察组血CRP水平显著降低（8．86±0．73mg／Lvs9．52±1．03mg／L）且显著低于对照组（10．01±1．26mg／Lvs9．65±0．89mg／L）。观察组的血脂在治疗12个月时较治疗前明显改善，血总胆固醇、低密度脂蛋白胆固醇和甘油三酯显著下降，高密度脂蛋白胆固醇升高（P〈0．01）。而观察组卒中发生率亦较对照组有下降趋势。结论阿托伐他汀可降低永久性心房颤动患者血浆CRP水平、改善血脂水平，对脑卒中有一定防治作用．

Objective To evaluate the effect of Atorvastatin on the level of c-reactive protein （CRP） and on the incidence of stroke in patients with atrim fibrillation. Methods 96 patients with permanent atrial fibrillation were randomized to the treatment group and the control group.The control group were given routine medication,while the treatment group were administrated with Atorvastatin,20mg served everyday,in addition to routine medication. After 12 months follow-up,the serum level of CRP and serum lipid levels were observed, occurrence of ischemie stroke was all recorded.. Results At 12 months follow-up, the serum level of ClIP in the treatment group were significantly not only lower than those in the control group （P〈 0.05）,but also lower than those before treatment. Furthermore the profile of serum lipid in the treatment group was ameliorated at the termination of treatment （P〈0.01） compared with that before therapy,whereas it was not the case in the control group. The incidence of stroke in the treatment group had a tendency to decrease than that in the control group. Conclusions Atorvastatin can effectively inhibit inflammatory reaction and to ameliorate serum lipid, and may help to prevent atrial fibrillation associated stroke.